GleamWall
中文EN

TRIB TRINITY BIOTECH PLC IFRS

In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 888721 · Fiscal year ends 12/31

Financial factors as of 2020-12-31 (FY2020), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY12.8%
TTM net income YoY77.9%
TTM EPS YoY—
Revenue 3-yr CAGR0.9%
Net income 3-yr CAGR—

Margins

Gross margin47.6%
Operating margin0.1%
Net margin-6.3%
FCF margin20.2%
EBITDA margin0.1%

Returns

ROE-512.3%
ROA-4.9%
ROIC (approx.)0.1%
Asset turnover0.78x

Leverage & solvency

Liabilities / assets101.7%
Debt / equity—
Current ratio3.08x
Interest coverage0.01x

Cash quality & payout

Operating cash flow / net income-3.72x
Accruals ratio-23.1%
Payout ratio—
Capex / revenue3.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20242024-12-31FY20232023-12-31
Income statement
Revenue$61.55M$56.83M
Cost of revenue$40.11M$37.38M
Gross profit$21.44M$19.45M
R&D expense$4.54M$4.38M
SG&A expense$28.82M$31.15M
Operating income-$21.16M-$27.05M
Interest expense$9.56M$11.05M
Pretax income-$30.73M-$36.93M
Income tax$486,000-$59,000
Net income-$31.79M-$24.02M
EBITDA-$20.96M-$27.05M
EPS (diluted)——
Balance sheet
Cash & equivalents$5.17M$3.69M
Receivables$16.07M$13.90M
Inventory$19.37M$19.93M
Current assets$41.12M$39.04M
PP&E, netmay include right-of-use assets (IFRS)$4.62M$1.89M
Total assets$103.29M$59.44M
Current liabilities$32.09M$15.04M
Short-term debt—$210,000
Long-term debt$210,000$210,000
Total debt$210,000$420,000
Total liabilities$138.47M$83.38M
Shareholders' equity-$35.18M-$23.95M
Net debt-$4.96M-$3.27M
Cash flow statement
Operating cash flow-$4.19M-$11.56M
Capital expenditure$405,000$803,000
Free cash flow-$4.60M-$12.36M
Investing cash flow-$22.97M$24.76M
Financing cash flow$28.81M-$16.04M
Depreciation & amortization$204,000$0
Stock-based compensation$1.32M$2.07M

Free plan shows the latest 2 periods; Pro shows all 10 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.